Replicor is a clinical-stage company developing novel NUCLEIC ACID-BASED POLYMERS (NAPs): oligonucleotides whose antiviral activity is strictly dependent on the polymer chemistry of oligonucleotides which can be preserved independently of the sequence of nucleotides present. NAPs have a very important safety advantage over all other existing oligonucleotide-based drugs such as aptamers, antisense oligonucleotides and siRNA: because NAP’s activity is not sequence dependent, NAPs can be engineered with sequences which retain antiviral activity but which do not have pro-inflammatory activity or off target effects common with other oligonucleotide-based drugs, rendering them safe and well tolerated.
Montreal, CA
7 (est)

Replicor Locations

Montreal, CA

Replicor Metrics

Replicor Summary

Replicor Company Life